Comparison of the Effectiveness of First-line Preventive Treatment of Migraine in Primary Care

ConditionMigraine
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorFundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

About this trial

This study, which is aimed at comparing the effectiveness of the most frequently used drugs in the first line in primary care for the preventive treatment of migraine (amitriptyline, flunarizine, topiramate and propranolol), is a multicentre, pragmatic, parallel group, open randomised trial. Adults (≥18) candidates for preventive treatment for migraine; those with a frequency of ≥4 monthly migraine days, and who agree to participate in the clinical trial, will be randomised to one of the 4 groups. Sample: 460 patients. The primary outcome will be the reduction in monthly migraine days, comparing amitriptyline, flunarizine and topiramate with propranolol.

Eligibility criteria

Qualifiers

None

Disqualifiers

People diagnosed with migraine who are not candidates for preventive migraine treatment

People diagnosed with chronic migraine (>15 days of headache per month, of which 8 are monthly migraine days)

Not having a smartphone

Simultaneous participation in another clinical trial

Trial design

Treatments tested in this trial

  • Topiramate
  • Flunarizine
  • Amitriptyline
  • Propranolol

Treatment groups

460 Participants
are divided into 4 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Lead sponsor

Institut Català de la Salut

Collaborator

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Collaborator